TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases
暂无分享,去创建一个
[1] J. Dayer,et al. Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis , 1995 .
[2] F. Breedveld,et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis. , 1999, Journal of immunology.
[3] D. Hommes,et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). , 1995, Gastroenterology.
[4] T. Hirano,et al. Structure and expression of human B cell stimulatory factor‐2 (BSF‐2/IL‐6) gene. , 1987, The EMBO journal.
[5] M. Feldmann,et al. Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[6] Kevin J. Tracey,et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.
[7] L. Klareskog,et al. Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[8] J. Ghrayeb,et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. , 1993, Arthritis and rheumatism.
[9] J. Woody,et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.
[10] Bharat B. Aggarwal,et al. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin , 1984, Nature.
[11] R. Day. Adverse reactions to TNF-α inhibitors in rheumatoid arthritis , 2002, The Lancet.
[12] F. Breedveld,et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[13] M. Feldmann,et al. Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis. , 1998, Arthritis and rheumatism.
[14] M. Feldmann,et al. INHIBITORY EFFECT OF TNFα ANTIBODIES ON SYNOVIAL CELL INTERLEUKIN-1 PRODUCTION IN RHEUMATOID ARTHRITIS , 1989, The Lancet.
[15] K. Tracey,et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin 1 beta and interleukin 6 appearance during lethal bacteremia , 1989, The Journal of experimental medicine.
[16] R N Maini,et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. , 2000, The New England journal of medicine.
[17] T. Taniguchi,et al. Structure and expression of a cloned cDNA for human interleukin-2 , 1983, Nature.
[18] M. Feldmann,et al. Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. , 1991, Arthritis and rheumatism.
[19] M. Feldmann,et al. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[20] M. Feldmann,et al. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? , 2001, Annual review of immunology.
[21] J. Woody,et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.
[22] E. Tindall,et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.
[23] M. Turner,et al. Expression of granulocyte‐macrophage colony‐stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor‐α , 1991, European journal of immunology.
[24] M. Feldmann,et al. ROLE OF ABERRANT HLA-DR EXPRESSION AND ANTIGEN PRESENTATION IN INDUCTION OF ENDOCRINE AUTOIMMUNITY , 1983, The Lancet.
[25] M. Turner,et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. , 1988, Clinical and experimental immunology.
[26] M. Weisman,et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. , 2003, Arthritis and rheumatism.
[27] T. Kishimoto,et al. Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis. Phase I/II clinical study. , 2003, The Journal of rheumatology.
[28] G. Janossy,et al. RHEUMATOID ARTHRITIS: A DISEASE OF T-LYMPHOCYTE/MACROPHAGE IMMUNOREGULATION , 1981, The Lancet.
[29] S. Johansson,et al. Letter: A radioimmunoassay for serum-alpha-fetoprotein based on commercial antisera. , 1974, Lancet.
[30] M. Feldmann,et al. Role of cytokines in rheumatoid arthritis. , 1996, Annual review of immunology.
[31] D. Kioussis,et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.
[32] M. Feldmann,et al. Synergy between anti-CD4 and anti-tumor necrosis factor in the amelioration of established collagen-induced arthritis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.